Antiaggregatory effects of picotamide in long-term treatment: A 2-year, double-blind placebo-controlled trial

Vascular Medicine

Volumn 2, Issue 4, 1997, Pages 292-295

  Cocozza, Manlio ^a   Milani, Massimo ^b,c   Picano, Tommaso ^a   Oliviero, Ugo ^a   Russo, Nicola ^a   Coto, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Novartis Farma   (Italy)

^c Italy   (Italy)

Author keywords

Antiplatelet drugs; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; PICOTAMIDE; THROMBOXANE A2; THROMBOXANE RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031428267     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9700200403     Document Type: Article

References (14)

1. Antiplateiet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320-31.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 1994; 308: 81-106.
3. Helgason C, Bolin K, Hoff J et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-36.
4. Grotemeyer K, Scharafinsk H, Husstedt I Two year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post stroke patients. Thromb Res 1993; 71: 397-403.
5. Gresele P, Deckmyn H, Arnout J, Nenct GG, Vermylen J. Characterization of N,N′-bis(3-picolyl)-4-methoy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonists in human platelets. Thromb Haemost 1989; 61: 479-84.
6. Violi F, Ghiselli A, Iuliano L, Praticò D, Alessandri C, Balsano F. Inhibition by picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmacol 1988; 33: 559-62.
7. Cattaneo M, Tenconi PM, Lecchi A, Mannucci PM, Bianchi Bonomi A. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. Thromb Res 1991; 62: 717-24.
8. Pulcinelli FM, Pignatelli P, Riondino S, Parisi S, Castiglioni C, Gazzaniga PP. Effect of picotamide on the calcium mobilization and phospholipase C activation in human platelets. Thromb Res 1994; 74: 453-61.
9. Violi F. Safety of picotamide, an antiplatelet agent, in an 18 month, double-blind, placebo controlled, multicenter trial in 2304 patients with peripheral vascular disease. Curr Ther Res 1993; 54: 111-21.
10. Balsano F, Violi F, ADEP Group. Effect of picotamide on the clinical progression of peripheral vascular disease: a double-blind placebo controlled study. Circulation 1993; 87: 1563-69.
11. Milani M, Longoni A, Maderna M. Effects of picotamide, an antiplatelet agent, on cardiovascular events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Clin Pharmacol 1996; 42: 782-85.
12. Cocozza M, Picano T, Oliviero U, Russo N, Coto V, Milani M. Effects of picotamide, an antithromboxane agent on carotid atherosclerotic evolution: a two-year, double blind, placebo controlled study in diabetic patients. Stroke 1995; 26: 597-601.
13. Cotè R, Battista R, Abrahamowicz M, Langlois Y, Bourque F, Mackey A. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing, Ann Intern Med 1995; 123: 649-55.
14. Cimminiello C, Milani M. Diabetes mellitus and peripheral vascular events: is aspirin effective in preventing vascular events? Diabetologia 1996; 39: 1402-404.